SLC5A2 and type 2 diabetes mellitus: The study population included 75 739 people with type 2 diabetes mellitus who initiated second line oral antidiabetic treatment with sulfonylureas, DPP-4 inhibitors, or SGLT-2 inhibitors and met all eligibility criteria (fig 2).